The Potential Benefit of Leptin Therapy Against Amyotrophic Lateral Sclerosis (ALS)

Overview

Journal Brain Behav

Specialty Psychology

Date 2021 Dec 22

PMID 34935299

Citations 7

Authors

Agueda Ferrer-Donato

Ana Contreras

Paloma Fernandez

Carmen M Fernandez-Martos

Affiliations

Soon will be listed here.

Abstract

Background: Targeting leptin could represent a rational strategy to treat amyotrophic lateral sclerosis (ALS), as previously clinical studies have shown its levels to be associated with a lower risk of ALS disease. However, very little is known about the potential influence of leptin in altering disease progression in ALS, as it has thus far been correlated with the protection exerted by increased fat mass stores.

Methods: We studied the impact of leptin treatment beginning at 42-days of age (asymptomatic stage of disease) in the TDP-43 (TDP43 ) transgenic (Tg) ALS mouse model.

Results: Our study shows that leptin treatment was associated with altered expression of adipokines and metabolic proteins in TDP43 mice. We also observed that weight loss decline was less prominent after leptin treatment in TDP43 mice relative to vehicle-treated animals. In TDP43 mice treated with leptin the disease duration lasted longer along with an improvement in motor performance relative to vehicle-treated animals.

Conclusions: Collectively, our results support leptin as a potential novel treatment approach for ALS.

Citing Articles

Alterations to metabolic hormones in amyotrophic lateral sclerosis and frontotemporal dementia postmortem human tissue.

Atkinson R, Collins J, Sreedharan J, King A, Fernandez-Martos C J Neuropathol Exp Neurol. 2024; 83(11):907-916.

PMID: 38917432 PMC: 11487092. DOI: 10.1093/jnen/nlae054.

Exploring the Role of Metabolic Hormones in Amyotrophic Lateral Sclerosis.

Motataianu A, Manescu I, Serban G, Barcutean L, Ion V, Balasa R Int J Mol Sci. 2024; 25(10).

PMID: 38791099 PMC: 11121721. DOI: 10.3390/ijms25105059.

Leptin haploinsufficiency exerts sex-dependent partial protection in SOD1 mice by reducing inflammatory pathways in the adipose tissue.

Fernandez-Beltran L, Ali Z, Larrad-Sanz A, Lopez-Carbonero J, Godoy-Corchuelo J, Jimenez-Coca I Sci Rep. 2024; 14(1):2671.

PMID: 38302474 PMC: 10834470. DOI: 10.1038/s41598-024-52439-z.

Multifunctional nanoparticle-mediated combining therapy for human diseases.

Li X, Peng X, Zoulikha M, Boafo G, Thapa Magar K, Ju Y Signal Transduct Target Ther. 2023; 9(1):1.

PMID: 38161204 PMC: 10758001. DOI: 10.1038/s41392-023-01668-1.

Emerging Trends in the Field of Inflammation and Proteinopathy in ALS/FTD Spectrum Disorder.

De Marchi F, Franjkic T, Schito P, Russo T, Nimac J, Chami A Biomedicines. 2023; 11(6).

PMID: 37371694 PMC: 10295684. DOI: 10.3390/biomedicines11061599.

References

Stallings N, Puttaparthi K, Luther C, Burns D, Elliott J . Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol Dis. 2010; 40(2):404-14. DOI: 10.1016/j.nbd.2010.06.017. View

Ferrer-Donato A, Contreras A, Fernandez P, Fernandez-Martos C . The potential benefit of leptin therapy against amyotrophic lateral sclerosis (ALS). Brain Behav. 2021; 12(1):e2465. PMC: 8785645. DOI: 10.1002/brb3.2465. View

Chen-Plotkin A, Lee V, Trojanowski J . TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol. 2010; 6(4):211-20. PMC: 2892118. DOI: 10.1038/nrneurol.2010.18. View

Wang W, Li L, Lin W, Dickson D, Petrucelli L, Zhang T . The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons. Hum Mol Genet. 2013; 22(23):4706-19. PMC: 3820133. DOI: 10.1093/hmg/ddt319. View

Kahn S, Zinman B, Haffner S, ONeill M, Kravitz B, Yu D . Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes. 2006; 55(8):2357-64. DOI: 10.2337/db06-0116. View

Hatzipetros T, Bogdanik L, Tassinari V, Kidd J, Moreno A, Davis C . C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS. Brain Res. 2013; 1584:59-72. DOI: 10.1016/j.brainres.2013.10.013. View

Bahor Z, Liao J, Macleod M, Bannach-Brown A, McCann S, Wever K . Risk of bias reporting in the recent animal focal cerebral ischaemia literature. Clin Sci (Lond). 2017; 131(20):2525-2532. PMC: 5869854. DOI: 10.1042/CS20160722. View

Seino Y, Fukushima M, Yabe D . GIP and GLP-1, the two incretin hormones: Similarities and differences. J Diabetes Investig. 2014; 1(1-2):8-23. PMC: 4020673. DOI: 10.1111/j.2040-1124.2010.00022.x. View

Ludolph A, Dorst J, Dreyhaupt J, Weishaupt J, Kassubek J, Weiland U . Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis. Ann Neurol. 2019; 87(2):206-216. DOI: 10.1002/ana.25661. View

10.

Medina D, Orr M, Oddo S . Accumulation of C-terminal fragments of transactive response DNA-binding protein 43 leads to synaptic loss and cognitive deficits in human TDP-43 transgenic mice. Neurobiol Aging. 2013; 35(1):79-87. DOI: 10.1016/j.neurobiolaging.2013.07.006. View

11.

Ioannides Z, Ngo S, Henderson R, McCombe P, Steyn F . Altered Metabolic Homeostasis in Amyotrophic Lateral Sclerosis: Mechanisms of Energy Imbalance and Contribution to Disease Progression. Neurodegener Dis. 2016; 16(5-6):382-97. DOI: 10.1159/000446502. View

12.

Wegorzewska I, Bell S, Cairns N, Miller T, Baloh R . TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A. 2009; 106(44):18809-14. PMC: 2762420. DOI: 10.1073/pnas.0908767106. View

13.

Farr S, Banks W, Morley J . Effects of leptin on memory processing. Peptides. 2005; 27(6):1420-5. DOI: 10.1016/j.peptides.2005.10.006. View

14.

Dang T, Lim N, Grubman A, Li Q, Volitakis I, White A . Increased metal content in the TDP-43(A315T) transgenic mouse model of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Front Aging Neurosci. 2014; 6:15. PMC: 3920072. DOI: 10.3389/fnagi.2014.00015. View

15.

Kuraszkiewicz B, Goszczynska H, Podsiadly-Marczykowska T, Piotrkiewicz M, Andersen P, Gromicho M . Potential Preventive Strategies for Amyotrophic Lateral Sclerosis. Front Neurosci. 2020; 14:428. PMC: 7264408. DOI: 10.3389/fnins.2020.00428. View

16.

Begley C, Ellis L . Drug development: Raise standards for preclinical cancer research. Nature. 2012; 483(7391):531-3. DOI: 10.1038/483531a. View

17.

Ferri A, Coccurello R . What is "Hyper" in the ALS Hypermetabolism?. Mediators Inflamm. 2017; 2017:7821672. PMC: 5610793. DOI: 10.1155/2017/7821672. View

18.

Lopez-Gomez J, Ballesteros-Pomar M, Torres-Torres B, Pintor de la Maza B, Penacho-Lazaro M, Palacio-Mures J . Malnutrition at diagnosis in amyotrophic lateral sclerosis (als) and its influence on survival: Using glim criteria. Clin Nutr. 2020; 40(1):237-244. DOI: 10.1016/j.clnu.2020.05.014. View

19.

Jawaid A, Gapp K, Schulz P . Mitochondrial dysfunction and decrease in body weight of transgenic knock-in mouse model for TDP-43: the question of glucose?. J Biol Chem. 2014; 289(26):18593. PMC: 4140249. DOI: 10.1074/jbc.L114.572651. View

20.

STEPHENS T, Basinski M, Bristow P, Bue-Valleskey J, Burgett S, Craft L . The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature. 1995; 377(6549):530-2. DOI: 10.1038/377530a0. View